Late effects of childhood leukemia therapy

Current Hematologic Malignancy Reports

Volumn 6, Issue 3, 2011, Pages 195-205

  Fulbright, Joy M ^a   Raman, Sripriya ^a   McClellan, Wendy S ^a   August, Keith J ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

ALL; AML; Cardiotoxicity; Children; Growth hormone deficiency; Infertility; Late effects; Leukemia; Neurocognitive deficits; Obesity; Pediatric; Psychosocial effects; Radiation; Secondary malignancies

Indexed keywords

ALKYLATING AGENT; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BRAIN NATRIURETIC PEPTIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLLITROPIN; GLUCOCORTICOID; GROWTH HORMONE; HUMAN GROWTH HORMONE; LEPTIN; LEPTIN RECEPTOR; LUTEINIZING HORMONE; METHOTREXATE; PREDNISONE; RAZOXANE; STEROID; TESTOSTERONE; TROPONIN T; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE DENSITY; BRAIN RADIATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CANCER SURVIVOR; CANCER THERAPY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD LEUKEMIA; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; DRUG MEGADOSE; EARLY MENOPAUSE; EMPLOYMENT STATUS; ENDOCRINE DISEASE; EVENT FREE SURVIVAL; FOLLOW UP; GLIOMA; GROWTH HORMONE DEFICIENCY; GROWTH INHIBITION; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; HYPOTHYROIDISM; INFERTILITY; INSULIN RESISTANCE; LUTEINIZING HORMONE BLOOD LEVEL; MALE INFERTILITY; MELANOMA; MENINGIOMA; MULTIMODALITY CANCER THERAPY; MYELODYSPLASTIC SYNDROME; MYOPATHY; NEUROPATHY; NEUROTOXICITY; OBESITY; OUTCOME ASSESSMENT; OVARY INSUFFICIENCY; PRECOCIOUS PUBERTY; PREMATURE LABOR; PROTEIN BLOOD LEVEL; PSYCHOSOCIAL DISORDER; QUALITY OF LIFE; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; REPRODUCTIVE TOXICITY; RISK ASSESSMENT; SECOND CANCER; SEX DIFFERENCE; SIDE EFFECT; SKULL IRRADIATION; SURVIVAL RATE; TESTOSTERONE BLOOD LEVEL; THYROID CANCER; THYROID DISEASE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; ENDOCRINE SYSTEM DISEASES; FERTILITY; GROWTH DISORDERS; HEART DISEASES; HUMANS; LEUKEMIA, MYELOID, ACUTE; OBESITY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; STRESS, PSYCHOLOGICAL;

EID: 80055062469     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0094-x     Document Type: Article

References (132)

1. Leisenring WM, Mertens AC, Armstrong GT, et al. Pediatric cancer survivorship research: experience of the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27:2319-27.
2. Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol. 2002;38:229-39. (Pubitemid 34258414)
3. Linabery AM, Ross JA. Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999. Cancer. 2008;113:2575-96.
4. Bhatia S, Sather HN, Pabustan OB, et al. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood. 2002;99:4257-64. (Pubitemid 34627190)
5. Borgmann A, Zinn C, Hartmann R, et al. Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. Eur J Cancer. 2008;44:257-68.
6. Mody R, Li S, Dover DC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood. 2008;111:5515-23.
7. Pui CH, Cheng C, Leung W, et al. Extended follow-up of longterm survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003;349:640-9. (Pubitemid 36975996)
8. Hijiya N, Hudson MM, Lensing S, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA. 2007;297:1207-15. (Pubitemid 46465729)
9. Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009; 27:2356-62.
10. Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the Children's Cancer Group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. Leukemia. 2010;24:285-97.
11. Banerjee J, Paakko E, Harila M, et al. Radiation-induced meningiomas: a shadow in the success story of childhood leukemia. Neuro Oncol. 2009;11:543-9.
12. Bien E, Stachowicz-Stencel T, Szalewska M, et al. Poor-risk high-grade gliomas in three survivors of childhood acute lymphoblastic leukaemia-an overview of causative factors and possible therapeutic options. Childs Nerv Syst. 2009;25:619-26.
13. Nathan PC, Wasilewski-Masker K, Janzen LA. Long-term outcomes in survivors of childhood acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009; 23:1065-82, vi-vii.
14. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030-43. (Pubitemid 351389536)
15. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808-15.
16. Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998;16:545-50. (Pubitemid 28135597)
17. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629-36. (Pubitemid 46179451)
18. Creutzig U, Diekamp S, Zimmermann M, Reinhardt D. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr Blood Cancer. 2007;48:651-62. (Pubitemid 46717611)
19. Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2008;100:1368-79.
20. Amigoni M, Giannattasio C, Fraschini D, et al. Low anthracyclines doses-induced cardiotoxicity in acute lymphoblastic leukemia long-term female survivors. Pediatr Blood Cancer. 2010; 55:1343-47.
21. Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997;15:1544-52. (Pubitemid 27167391)
22. Kremer LC, van Dalen EC, Offringa M, Voute PA. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol. 2002;13:503-12. (Pubitemid 34461132)
23. Kremer LC, van Dalen EC, Offringa M, et al. Anthracyclineinduced clinical heart failure in a cohort of 607 children: longterm follow-up study. J Clin Oncol. 2001;19:191-6. (Pubitemid 32063496)
24. Kremer LC, van der Pal HJ, Offringa M, et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol. 2002;13:819-29. (Pubitemid 34752678)
25. Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol. 2010;28:1308-15.
26. Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer. 2003;97:1991-8. (Pubitemid 36397277)
27. Sorensen K, Levitt G, Bull C, et al. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. J Clin Oncol. 1997;15:61-8. (Pubitemid 27020558)
28. Rathe M, Carlsen NL, Oxhoj H, Nielsen G. Long-term cardiac follow-up of children treated with anthracycline doses of 300 mg/m2 or less for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010; 54:444-8.
29. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351:145-53. (Pubitemid 38886649)
30. Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol. 2001;19:3163-72. (Pubitemid 32591432)
31. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738-43.
32. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010; 11:950-61.
33. Tebbi CK, London WB, Friedman D, et al. Dexrazoxaneassociated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. 2007;25:493-500. (Pubitemid 350002954)
34. Barry EV, Vrooman LM, Dahlberg SE, et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol. 2008;26:1106-11.
35. Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol. 2002;20:1677-82. (Pubitemid 34260550)
36. Levitt GA, Dorup I, Sorensen K, Sullivan I. Does anthracycline administration by infusion in children affect late cardiotoxicity? Br J Haematol. 2004;124:463-8. (Pubitemid 38230590)
37. Steinherz PG, Redner A, Steinherz L, et al. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol. Cancer. 1993;72:3120-30. (Pubitemid 23335062)
38. Erkus B, Demirtas S, Yarpuzlu AA, et al. Early prediction of anthracycline induced cardiotoxicity. Acta Paediatr. 2007;96:506-9. (Pubitemid 46466109)
39. Hayakawa H, Komada Y, Hirayama M, et al. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol. 2001;37:4-9. (Pubitemid 32613628)
40. Bryant J, Picot J, Baxter L, et al. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review. Eur J Cancer. 2007;43:1959-66. (Pubitemid 47299200)
41. Rajic V, Aplenc R, Debeljak M, et al. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma. 2009;50:1693-8.
42. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer. 2008;112:2789-95. (Pubitemid 351969225)
43. Cousens P, Waters B, Said J, Stevens M. Cognitive effects of cranial irradiation in leukaemia: a survey and meta-analysis. J Child Psychol Psychiatry. 1988;29:839-52.
44. Harila MJ, Winqvist S, Lanning M, et al. Progressive neurocognitive impairment in young adult survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009; 53:156-61.
45. Peterson CC, Johnson CE, Ramirez LY, et al. A meta-analysis of the neuropsychological sequelae of chemotherapy-only treatment for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;51:99-104. (Pubitemid 351717398)
46. Goldsby RE, Liu Q, Nathan PC, et al. Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2010; 28:324-31.
47. Bowers DC, Liu Y, Leisenring W, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006;24:5277-82. (Pubitemid 46631374)
48. Campbell LK, Scaduto M, Sharp W, et al. A meta-analysis of the neurocognitive sequelae of treatment for childhood acute lymphocytic leukemia. Pediatr Blood Cancer. 2007;49:65-73. (Pubitemid 46847070)
49. Mitby PA, Robison LL, Whitton JA, et al. Utilization of special education services and educational attainment among long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer. 2003;97:1115-26. (Pubitemid 36173166)
50. Kingma A, Rammeloo LA, van Der Does-van den Berg A, et al. Academic career after treatment for acute lymphoblastic leukaemia. Arch Dis Child. 2000;82:353-7. (Pubitemid 30307760)
51. Harila-Saari AH, Lahteenmaki PM, Pukkala E, et al. Scholastic achievements of childhood leukemia patients: a nationwide, register-based study. J Clin Oncol. 2007;25:3518-24. (Pubitemid 47310890)
52. Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol. 2008;9:257-68. (Pubitemid 351722945)
53. Kadan-Lottick NS, Zeltzer LK, Liu Q, et al. Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. J Natl Cancer Inst. 2010;102:881-93.
54. Silber JH, Radcliffe J, Peckham V, et al. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. J Clin Oncol. 1992;10:1390-6. (Pubitemid 23059921)
55. Rubenstein CL, Varni JW, Katz ER. Cognitive functioning in long-term survivors of childhood leukemia: a prospective analysis. J Dev Behav Pediatr. 1990;11:301-5.
56. Jankovic M, Brouwers P, Valsecchi MG, et al. Association of 1800 cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukaemia. ISPACC. International Study Group on Psychosocial Aspects of Childhood Cancer. Lancet. 1994;344:224-7. (Pubitemid 24229009)
57. Waber DP, Tarbell NJ, Kahn CM, et al. The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia. J Clin Oncol. 1992;10:810-7.
58. Bleyer WA, Fallavollita J, Robison L, et al. Influence of age, sex, and concurrent intrathecal methotrexate therapy on intellectual function after cranial irradiation during childhood: a report from the Children's Cancer Study Group. Pediatr Hematol Oncol. 1990;7:329-38. (Pubitemid 20376681)
59. Waber DP, Gioia G, Paccia J, et al. Sex differences in cognitive processing in children treated with CNS prophylaxis for acute lymphoblastic leukemia. J Pediatr Psychol. 1990;15:105-22. (Pubitemid 20156190)
60. Jannoun L. Are cognitive and educational development affected by age at which prophylactic therapy is given in acute lymphoblastic leukaemia? Arch Dis Child. 1983;58:953-8. (Pubitemid 14215832)
61. Moore IM, Kramer JH, Wara W, et al. Cognitive function in children with leukemia. Effect of radiation dose and time since irradiation. Cancer. 1991;68:1913-7.
62. Moleski M. Neuropsychological, neuroanatomical, and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia. Arch Clin Neuropsychol. 2000;15:603-30.
63. Spiegler BJ, Kennedy K, Maze R, et al. Comparison of longterm neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or highdose or very high-dose intravenous methotrexate. J Clin Oncol. 2006;24:3858-64. (Pubitemid 46630732)
64. Anderson VA, Godber T, Smibert E, et al. Cognitive and academic outcome following cranial irradiation and chemotherapy in children: a longitudinal study. Br J Cancer. 2000;82:255-62. (Pubitemid 30045367)
65. Langer T, Martus P, Ottensmeier H, et al. CNS late-effects after ALL therapy in childhood. Part III: neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory. Med Pediatr Oncol. 2002;38:320-8. (Pubitemid 34493111)
66. Butler RW, Hill JM, Steinherz PG, et al. Neuropsychologic effects of cranial irradiation, intrathecal methotrexate, and systemic methotrexate in childhood cancer. J Clin Oncol. 1994;12:2621-9.
67. Anderson V, Smibert E, Ekert H, Godber T. Intellectual, educational, and behavioural sequelae after cranial irradiation and chemotherapy. Arch Dis Child. 1994;70:476-83. (Pubitemid 24201061)
68. Clarke M, Gaynon P, Hann I, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol. 2003;21:1798-809. (Pubitemid 46646217)
69. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360:2730-41.
70. Cole PD, Kamen BA. Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia. Ment Retard Dev Disabil Res Rev. 2006;12:174-83. (Pubitemid 44646326)
71. Kingma A, Van Dommelen RI, Mooyaart EL, et al. No major cognitive impairment in young children with acute lymphoblastic leukemia using chemotherapy only: a prospective longitudinal study. J Pediatr Hematol Oncol. 2002;24:106-14. (Pubitemid 34150549)
72. Copeland DR, Moore 3rd BD, Francis DJ, et al. Neuropsychologic effects of chemotherapy on children with cancer: a longitudinal study. J Clin Oncol. 1996;14:2826-35. (Pubitemid 26329670)
73. Raymond-Speden E, Tripp G, Lawrence B, Holdaway D. Intellectual, neuropsychological, and academic functioning in long-term survivors of leukemia. J Pediatr Psychol. 2000;25:59-68. (Pubitemid 30112226)
74. Buizer AI, de Sonneville LM, Veerman AJ. Effects of chemotherapy on neurocognitive function in children with acute lymphoblastic leukemia: a critical review of the literature. Pediatr Blood Cancer. 2009; 52:447-54.
75. Kaemingk KL, Carey ME, Moore IM, et al. Math weaknesses in survivors of acute lymphoblastic leukemia compared to healthy children. Child Neuropsychol. 2004;10:14-23. (Pubitemid 38418930)
76. Carey ME, Haut MW, Reminger SL, et al. Reduced frontal white matter volume in long-term childhood leukemia survivors: a voxel-based morphometry study. AJNR Am J Neuroradiol. 2008;29:792-7. (Pubitemid 351571566)
77. Espy KA, Moore IM, Kaufmann PM, et al. Chemotherapeutic CNS prophylaxis and neuropsychologic change in children with acute lymphoblastic leukemia: a prospective study. J Pediatr Psychol. 2001;26:1-9. (Pubitemid 32099696)
78. Reddick WE, Shan ZY, Glass JO, et al. Smaller white-matter volumes are associated with larger deficits in attention and learning among long-term survivors of acute lymphoblastic leukemia. Cancer. 2006;106:941-9. (Pubitemid 43238463)
79. Buizer AI, de Sonneville LM, van den Heuvel-Eibrink MM, Veerman AJ. Chemotherapy and attentional dysfunction in survivors of childhood acute lymphoblastic leukemia: effect of treatment intensity. Pediatr Blood Cancer. 2005;45:281-90. (Pubitemid 41077161)
80. Hill DE, Ciesielski KT, Sethre-Hofstad L, et al. Visual and verbal short-term memory deficits in childhood leukemia survivors after intrathecal chemotherapy. J Pediatr Psychol. 1997;22:861-70. (Pubitemid 28086830)
81. Mulhern RK, Wasserman AL, Fairclough D, Ochs J. Memory function in disease-free survivors of childhood acute lymphocytic leukemia given CNS prophylaxis with or without 1,800 cGy cranial irradiation. J Clin Oncol. 1988;6:315-20. (Pubitemid 18065937)
82. Buizer AI, De Sonneville LM, van den Heuvel-Eibrink MM, et al. Visuomotor control in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. J Int Neuropsychol Soc. 2005;11:554-65. (Pubitemid 41478988)
83. Iuvone L, Mariotti P, Colosimo C, et al. Long-term cognitive outcome, brain computed tomography scan, and magnetic resonance imaging in children cured for acute lymphoblastic leukemia. Cancer. 2002;95:2562-70. (Pubitemid 35424043)
84. Waber DP, Carpentieri SC, Klar N, et al. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J Pediatr Hematol Oncol. 2000;22:206-13. (Pubitemid 32268304)
85. Kadan-Lottick NS, Brouwers P, Breiger D, et al. A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia. Blood. 2009;114:1746-52.
86. von der Weid N, Mosimann I, Hirt A, et al. Intellectual outcome in children and adolescents with acute lymphoblastic leukaemia treated with chemotherapy alone: age- and sex-related differences. Eur J Cancer. 2003;39:359-65. (Pubitemid 36140054)
87. Brown RT, Madan-Swain A, Walco GA, et al. Cognitive and academic late effects among children previously treated for acute lymphocytic leukemia receiving chemotherapy as CNS prophylaxis. J Pediatr Psychol. 1998;23:333-40. (Pubitemid 28432425)
88. Darzy KH, Shalet SM. Hypopituitarism following radiotherapy revisited. Endocr Dev. 2009; 15:1-24.
89. Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist. 2004;10:293-310. (Pubitemid 39492075)
90. Linsenmeier C, Thoennessen D, Negretti L, et al. Total body irradiation (TBI) in pediatric patients. A single-center experience after 30 years of low-dose rate irradiation. Strahlenther Onkol. 2010;186:614-20.
91. Darzy KH. Radiation-induced hypopituitarism after cancer therapy: who, how and when to test. Nat Clin Pract Endocrinol Metab. 2009;5:88-99.
92. Haddy TB, Mosher RB, Nunez SB, Reaman GH. Growth hormone deficiency after chemotherapy for acute lymphoblastic leukemia in children who have not received cranial radiation. Pediatr Blood Cancer. 2006;46:258-61. (Pubitemid 43076079)
93. Viana MB, Vilela MI. Height deficit during and many years after treatment for acute lymphoblastic leukemia in children: a review. Pediatr Blood Cancer. 2008;50:509-16. discussion 517.
94. Vilela MI, Viana MB. Longitudinal growth and risk factors for growth deficiency in children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2007;48:86-92. (Pubitemid 44871597)
95. Alves CH, Kuperman H, Dichtchekenian V, et al. Growth and puberty after treatment for acute lymphoblastic leukemia. Rev Hosp Clin Fac Med Sao Paulo. 2004;59:67-70.
96. Nandagopal R, Laverdiere C, Mulrooney D, et al. Endocrine late effects of childhood cancer therapy: a report from the Children's Oncology Group. Horm Res. 2008;69:65-74.
97. Gurney JG, Ness KK, Sibley SD, et al. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer. 2006;107:1303-12. (Pubitemid 44452780)
98. Link K, Moell C, Garwicz S, et al. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. J Clin Endocrinol Metab. 2004;89:5003-12. (Pubitemid 39391441)
99. Follin C, Thilén U, Osterberg K, et al. Cardiovascular risk, cardiac function, physical activity, and quality of life with and without long-term growth hormone therapy in adult survivors of childhood acute lymphoblastic leukemia. J Clin Endocrinol Metab. 2010;95:3726-35.
100. Bell J, Parker KL, Swinford RD, et al. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010;95:167-77.
101. Chow EJ, Friedman DL, Yasui Y, et al. Timing of menarche among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2008;50:854-8. (Pubitemid 351356099)
102. van Santen HM, Vulsma T, Dijkgraaf MG, et al. No damaging effect of chemotherapy in addition to radiotherapy on the thyroid axis in young adult survivors of childhood cancer. J Clin Endocrinol Metab. 2003;88:3657-63. (Pubitemid 37034510)
103. Delvecchio M, Cecinati V, Brescia LP, et al. Thyroid function and thyroid autoimmunity in childhood acute lymphoblastic leukemia off-therapy patients treated only with chemotherapy. J Endocrinol Invest. 2010;33:135-9.
104. Bhatti P, Veiga LH, Ronckers CM, et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res. 2010;174:741-52.
105. Einaudi S, Bertorello N, Masera N, et al. Adrenal axis function after high-dose steroid therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50:537-41. (Pubitemid 351155821)
106. Kuperman H, Damiani D, Chrousos GP, et al. Evaluation of the hypothalamic-pituitary-adrenal axis in children with leukemia before and after 6 weeks of high-dose glucocorticoid therapy. J Clin Endocrinol Metab. 2001;86:2993-6. (Pubitemid 32673454)
107. Kaste SC, Rai SN, Fleming K, et al. Changes in bone mineral density in survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2006;46:77-87. (Pubitemid 41779322)
108. Benmiloud S, Steffens M, Beauloye V, et al. Long-term effects on bone mineral density of different therapeutic schemes for acute lymphoblastic leukemia or non-Hodgkin lymphoma during childhood. Horm Res Paediatr. 2010; 74:241-50.
109. Ross JA, Oeffinger KC, Davies SM, et al. Genetic variation in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2004;22:3558-62. (Pubitemid 41103662)
110. Dalton VK, Rue M, Silverman LB, et al. Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment. J Clin Oncol. 2003;21:2953-60. (Pubitemid 46621847)
111. Asner S, Ammann RA, Ozsahin H, et al. Obesity in long-term survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;51:118-22. (Pubitemid 351717401)
112. Gofman I, Ducore J. Risk factors for the development of obesity in children surviving ALL and NHL. J Pediatr Hematol Oncol. 2009;31:101-7.
113. Garmey EG, Liu Q, Sklar CA, et al. Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2008;26:4639-45.
114. Lowas S, Malempati S, Marks D. Body mass index predicts insulin resistance in survivors of pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009;53:58-63.
115. Marquis A,Kuehni CE, Strippoli MP, et al. Spermanalysis of patients after successful treatment of childhood acute lymphoblastic leukemia with chemotherapy. Pediatr Blood Cancer. 2010;55:208-10.
116. Romerius P, Stahl O, Moell C, et al. Hypogonadism risk in men treated for childhood cancer. J Clin Endocrinol Metab. 2009;94:4180-6.
117. van Casteren NJ, van der Linden GH, Hakvoort-Cammel FG, et al. Effect of childhood cancer treatment on fertility markers in adult male long-term survivors. Pediatr Blood Cancer. 2009; 52:108-12.
118. Green DM, Kawashima T, Stovall M, et al. Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2010; 28:332-9.
119. Byrne J, Fears TR, Mills JL, et al. Fertility of long-term male survivors of acute lymphoblastic leukemia diagnosed during childhood. Pediatr Blood Cancer. 2004;42:364-72. (Pubitemid 38327632)
120. Chemaitilly W, Mertens AC, Mitby P, et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab. 2006;91:1723-8.
121. Sklar CA, Mertens AC, Mitby P, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst. 2006;98:890-6. (Pubitemid 44018918)
122. Green DM, Kawashima T, Stovall M, et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2009; 27:2677-85.
123. Byrne J, Fears TR, Mills JL, et al. Fertility in women treated with cranial radiotherapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2004;42:589-97. (Pubitemid 38669746)
124. Mueller BA, Chow EJ, Kamineni A, et al. Pregnancy outcomes in female childhood and adolescent cancer survivors: a linked cancerbirth registry analysis. Arch Pediatr Adolesc Med. 2009;163:879-86.
125. Signorello LB, Cohen SS, Bosetti C, et al. Female survivors of childhood cancer: preterm birth and low birth weight among their children. J Natl Cancer Inst. 2006;98:1453-61. (Pubitemid 44605590)
126. Green DM, Whitton JA, Stovall M, et al. Pregnancy outcome of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Am J Obstet Gynecol. 2002;187:1070-80. (Pubitemid 35178413)
127. Eiser C. Beyond survival: quality of life and follow-up after childhood cancer. J Pediatr Psychol. 2007;32:1140-50. (Pubitemid 47622297)
128. Pang JW, Friedman DL, Whitton JA, et al. Employment status among adult survivors in the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2008;50:104-10. (Pubitemid 350234273)
129. Seitzman RL, Glover DA, Meadows AT, et al. Self-concept in adult survivors of childhood acute lymphoblastic leukemia: a cooperative Children's Cancer Group and National Institutes of Health study. Pediatr Blood Cancer. 2004;42:230-40. (Pubitemid 38235073)
130. Pakakasama S, Veerakul G, Sosothikul D, et al. Late effects in survivors of childhood acute lymphoblastic leukemia: a study from Thai Pediatric Oncology Group. Int J Hematol. 2010;91:850-4.
131. Harila MJ, Salo J, Lanning M, et al. High health-related quality of life among long-term survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010; 55:331-6.
132. Recklitis CJ, Diller LR, Li X, et al. Suicide ideation in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2010;28:655-61.